Markey Kristina, Axel Lisen, Ahnen Dennis
Denver Department of Veterans Affairs Medical Center and University of Colorado Hospital Hereditary Cancer Clinic, 1055 Clermont Street, Denver, CO 80220, USA.
Curr Gastroenterol Rep. 2002 Oct;4(5):404-13. doi: 10.1007/s11894-002-0011-5.
Approximately 5% of colorectal cancers are associated with one of the autosomal dominant hereditary cancer syndromes. The two most common familial colon cancer syndromes are familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC). The causative mutation can be identified in many families with these syndromes by genetic testing of an affected individual. If an affected individual tests positive for a disease-causing mutation, genetic testing of unaffected, at-risk family members can be performed to determine whether they have inherited the cancer-susceptibility mutation, and a personalized cancer surveillance strategy can be devised. Genetic testing significantly enhances cancer risk assessment in these families. However, the complicated nature of result interpretation and the emotional impact of the result necessitate that testing be carried out in conjunction with patient education and informed consent by a physician who has a keen appreciation for the inherent challenges. This article describes the genetic testing strategy in HNPCC and FAP.
大约5%的结直肠癌与常染色体显性遗传性癌症综合征之一相关。两种最常见的家族性结肠癌综合征是家族性腺瘤性息肉病(FAP)和遗传性非息肉病性结直肠癌(HNPCC)。通过对受影响个体进行基因检测,在许多患有这些综合征的家族中可以识别出致病突变。如果受影响个体的致病突变检测呈阳性,则可以对未受影响的高危家庭成员进行基因检测,以确定他们是否遗传了癌症易感性突变,并制定个性化的癌症监测策略。基因检测显著提高了这些家族的癌症风险评估。然而,结果解读的复杂性以及结果对情绪的影响使得检测必须在患者接受教育并在一位充分认识到内在挑战的医生的指导下获得知情同意后进行。本文描述了HNPCC和FAP的基因检测策略。